Business ❯ Healthcare ❯ Pharmaceuticals

Research and Development

Clinical Trials Drug Development Oncology In-process Research and Development (IPR&D) Product Candidates Pipeline Development Expense Management Inflammation Transplant Medications Government Policies Artificial Intelligence Pfizer Inc. Investigational Medicines In Vitro Diagnostics Cost Sharing

Pfizer Recasts Post‑COVID Outlook With Lower 2026 Guide and Bigger R&D Push

Management says pipeline advances together with roughly $9.7 billion in cost cuts should restore earnings by 2029.

Pfizer's 7% Dividend Faces Real Risk After $14.6 Billion in Payouts

Virax Biolabs Signs Exclusive ImmuneSelect Supply Deal With Fosun Diagnostics

Bristol Myers Squibb to Deploy Anthropic’s Claude Across Global Operations

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises